Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

5e408001-c696-4bc8-bd24-90434456b72d - samples

ABSTRACT: The goal of this study is to characterize immune cell populations by single cell RNA-sequencing (scRNA-seq) in tumor and uninvolved normal tissues from non-small cell lung cancer (NSCLC) patients with resectable non-small cell lung cancer and who received neoadjuvant chemoimmunotherapy. scRNA-seq was performed on seven pairs of tumor and normal tissues as well as one lymph node (LN) sample. Data set includes pair-end fastq files for single cell RNA sequencing of 7 neo-immuno patients. (Total 15 samples and 50 runs).

PROVIDER: EGAD00001009778 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

Single cell RNA-sequencing of tissues from NSCLC patients treated with chemoimmunotherapy

Project description:The goal of this study is to characterize immune cell populations by single cell RNA-sequencing (scRNA-seq) in tumor and uninvolved normal tissues from non-small cell lung cancer (NSCLC) patients with resectable non-small cell lung cancer and who received neoadjuvant chemoimmunotherapy. scRNA-seq was performed on seven pairs of tumor and normal tissues as well as one lymph node (LN) sample.

| EGAS00001006728 | EGA

Studing chemo- and immuno-resistance in non-small cell lung cancer (NSCLC) NCI-H2228 cell line

Project description:Non-small cell lung cancer (NSCLC) has a chemo-immuno-resistant phenotype. This study aims to elucidate druggable molecular pathways underlying such chemo-immuno-resistance.

2026-04-13 | GSE294588 | GEO

Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing

Project description:To address the potential therapy-resistant mechanisms and underly the changes of tumor microenvironment (TME) after immunotherapy, we performed scRNA-seq and bulk RNA-seq from the patients with resectable non-small cell lung cancer (NSCLC) before and after PD-1 blockade combined with chemotherapy. We found that the combined therapy significantly remodeled the immune cell compartments in the TME. Patients with different pathologic responses had distinct characteristics of malignant cells and immune cell compositions. Our study provided several potential biomarkers for future immunotherapy and novel strategies to improve response.

2023-03-21 | GSE207422 | GEO

Homo sapiens

Project description:Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer

| PRJNA134849 | ENA

Project description:Microbial Characterization of Non-small Cell Lung Cancer Tissues and Adjacent Healthy Tissues

| PRJNA680529 | ENA

Studing chemo- and immuno-resistance in non-small cell lung cancer (NSCLC) NCI-H2228 cell line

Project description:Studing chemo- and immuno-resistance in non-small cell lung cancer (NSCLC) NCI-H2228 cell line

| PRJNA1250546 | ENA

Project description:Exploring gut microbiome in predicting efficacy of immuno-therapy in non-small cell lung cancer

| PRJNA866654 | ENA

Homo sapiens

Project description:Non Small Cell Lung Cancer

| PRJNA90997 | ENA

Postnatal expansion of the lymph node stromal cell pool towards reticular and CD34+ stromal cell subsets [scRNA-seq III]

Project description:Gut-draining mesenteric lymph nodes (mLN) provide the framework and microenvironment to shape intestinal adaptive immune responses. We previously delineated transcriptional signatures in LN stromal cells (SC), pointing to tissue-specific variability in composition and immuno-modulatory function of SCs. Here, we dissect the tissue-specific epigenomic DNA accessibility and CpG methylation landscape of LN non-endothelial SCs and identify a microbiota-independent core epigenomic signature of LN SCs. By combined analysis of transcription factor (TF) binding sites together with the gene expression profiles of non-endothelial SCs, we delineated TFs poising skin-draining peripheral LN (pLN) SCs for pro-inflammatory responses. Furthermore, using scRNA-seq, we dissected the developmental trajectory of mLN SCs derived from postnatal to aged mice, identifying two distinct putative progenitors, namely CD34+ SC and fibroblastic reticular stromal cell (FRC) progenitors, which both feed the rapid postnatal LN expansion. Finally, we identified Irf3 as a key differentiation TF inferred from the epigenomic signature of mLN SCs that is dynamically expressed along the differentiation trajectories of FRCs, and validated Irf3 as a regulator of Cxcl9+ FRC differentiation. Together, our data constitute a comprehensive transcriptional and epigenomic map of mLN development and dissect location-specific, microbiota-independent properties of mLN non-endothelial SCs. As such, our findings represent a valuable resource to identify core transcriptional regulators that impinge on the developing mLN early in life, thereby shaping long-lasting intestinal adaptive immune responses.

2022-10-07 | GSE193709 | GEO

Postnatal expansion of the lymph node stromal cell pool towards reticular and CD34+ stromal cell subsets [ATAC-seq]

2022-10-07 | GSE171897 | GEO